CXCR4 and lung carcinoma: Moreover, through the lentiviral transduction of two different shRNAs (shERα#1 and shERα#2) or the treatment with a selective ERα antagonist, we proved that the regulatory pathway is through the production of macrophage CXCL12 to activate its receptor, CXCR4, on lung cancer cells.